

Applicants: Mark Ledebøer et al.  
Application No.: 10/005,133

### REMARKS

#### The Response

##### *Double Patenting*

The Examiner has rejected claims 1-5, 17, 20 and 21 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-3, 5 and 12 of United States Patent 6,884,804 B2 (hereafter “the ‘804 patent”).

Applicants provide herewith a terminal disclaimer over the ‘804 patent, thereby obviating this rejection.

#### Conclusion

Applicants request that the Examiner consider applicants’ arguments and allow the claims to pass to issue. Should the Examiner deem expedient a telephone discussion to further the prosecution of the above application, applicants request that the Examiner contact the undersigned at his convenience.

Respectfully submitted,

/Karen E. Brown/  
Karen E. Brown  
Reg. No. 43,866  
Attorney for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6168  
Fax: (617) 444-6483